ReviewFrontiers in allergy2026
Emerging molecular and environmental biomarkers of shrimp allergy in African Americans in the US.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shrimp allergy (SA), a major cause of food-induced anaphylaxis, represents a disproportionate and under-characterized burden among African American (AA) populations in the United States. Unlike many childhood food allergies, SA is often persistent and commonly presents in adolescence or adulthood, suggesting a role for cumulative environmental exposures in disrupting oral tolerance. A key diagnostic challenge in AA communities is the high prevalence of IgE sensitization to shrimp tropomyosin (Pen a 1), which shares strong structural homology with cockroach and house dust mite tropomyosins, leading to frequent cross-reactive but clinically irrelevant sensitization in urban settings. This review critically examines molecular and environmental biomarkers of SA with a focus on AA populations. We assess the limitations of extract-based IgE testing and component-resolved diagnostics, highlighting how single-component assays may overestimate true clinical allergy. We emphasize the added value of functional assays, particularly the basophil activation test, in distinguishing sensitization from challenge-confirmed allergies. Mechanistically, we discuss how chronic exposure to indoor arthropod allergens, air pollution, and socioenvironmental stressors may drive epithelial barrier dysfunction, IL-33 release, and amplification of type 2 immune pathways, lowering reaction thresholds and influencing disease persistence. We identify key gaps, including limited oral food challenge-confirmed data and underrepresentation of AA cohorts. Finally, we propose equity-centered, integrative research frameworks combining molecular diagnostics, functional assays, environmental assessment, and multi-omics to improve diagnostic precision and advance clinical equity in SA care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.